Business
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity\r\n \r\n \r\n\r\n\r\nZomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity\r\n\r\n\r\n\r\n\r\n\r\nZomedica surpasses $8 million in first quarter revenue for the first time and delivers record year-over-year revenue for 21st straight quarter. ANN ARBOR, MI / ACCESS Newswire / May 6, 2026 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2026.\r\n \"Delivering 35% growth and achieving record year-over-year revenue for the 21st consecutive quarter reflects the consistency of our execution and the growing demand for our products and services. Surpassing $8 million in first quarter revenue for the first time is a meaningful milestone, particularly given that, seasonally, the first quarter has historically been our lowest quarterly period from a revenue perspective\" said Larry Heaton, Chief Executive Officer of Zomedica.\r\n \"Performance in the quarter was driven by strong performance of our PulseVet® and Assisi® therapeutic device products, continued adoption of our diagnostic offerings, particularly our TRUFORMA® platform, and contributions from our newly formed Development Services segment. As a result, we delivered the strongest first quarter in our history, exceeding the prior record of $6.5 million set in the first quarter of 2025.\r\n \"During the quarter, we continued to execute on our strategy to build a leading equine and companion animal healthcare company. We launched our AI-enabled TRUVIEW® digital microscopy and telepathology platform in January and an agreement with Moichor, Inc., to distribute the device to their customers in February. In March, we announced a collaboration with Boehringer Ingelheim Animal Health Inc., a global leader in the animal health industry, to enhance early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses. Integrating our TRUFORMA platform and including equine endogenous ACTH (eACTH) and eq...